Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release
Article 2025 en
Authors
AR
Andreas Reif
BB
Bernhard T. Baune
JB
Jozefien Buyze
Abstract
1 min read
Esketamine NS produced superior improvements in HRQoL compared with quetiapine XR, indicating positive impacts on aspects of patients' lives that matter to them, alongside clinical symptoms of TRD.
Roger S. McIntyre, István Bitter, Jozefien Buyze, Andrea Fagiolini, Yordan Godinov, Philip Gorwood, Tetsuro Ito, Albino J. Oliveira‐Maia, Eduard Vieta, Tamara Werner‐Kiechle, Allan H. Young, Andreas Reif
Eduard Vieta, N. Ahmed, C. Arango, Anthony J. Cleare, Koen Demyttenaere, Markus Dold, Tetsuro Ito, Y. Kambarov, Stephanie Krüger, Pierre‐Michel Llorca, Roger S. McIntyre, Gabriele Sani, C. von Holt, B. Rive
Tom H. Oreel, Denny Borsboom, Sacha Epskamp, Iris D. Hartog, Justine E. Netjes, Pythia T. Nieuwkerk, José P.S. Henriques, Michael Scherer‐Rath, Hanneke W.M. van Laarhoven, Mirjam A. G. Sprangers
Jake Thompson, Julia Lai‐Kwon, Rachael L. Morton, Alexander Guminski, Maria Gonzalez, Victoria Atkinson, Shahneen Sandhu, Michael P. Brown, Alexander M. Menzies, Grant A. McArthur, Serigne Lo, Georgina V. Long, Iris Bartula
Discussion(0)
No comments yet. Be the first to comment.